MEDI5752

BIOLOGICAL6 trials

Conditions

Advanced Renal Cell CarcinomaAdvanced Solid TumorAdvanced Solid TumorsAdvanced or Metastatic NSCLCMetastatic Non-Small Cell Lung Cancer (NSCLC)Selected Advanced Solid Tumors

Phase 1

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Active, not recruitingNCT03530397

MedImmune LLCSelected Advanced Solid Tumors

Start: 2018-04-24End: 2025-12-30Updated: 2024-06-24

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Active, not recruitingNCT03819465

AstraZenecaMetastatic Non-Small Cell Lung Cancer (NSCLC)

Start: 2018-12-27End: 2026-03-26Updated: 2026-02-11

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Active, not recruitingNCT04522323

MedImmune LLCAdvanced Renal Cell Carcinoma

Start: 2020-08-05End: 2025-09-26Updated: 2025-07-25

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruitingNCT04612751

AstraZenecaAdvanced or Metastatic NSCLC

Start: 2021-02-02End: 2026-04-30Updated: 2025-12-18

MEDI5752 in Japanese Patients With Advanced Solid Tumors.

CompletedNCT05685472

AstraZenecaAdvanced Solid Tumors

Start: 2022-12-08End: 2025-07-29Updated: 2025-08-08

Phase 2

MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Not yet recruitingNCT05888857

Institut BergoniéAdvanced Solid Tumor

Start: 2025-09-30End: 2028-09-30Target: 102Updated: 2025-08-13

2026-02-17

MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.

2025-11-07

First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).

Journal of Clinical Oncology2025-05-285 citations

Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4

2025-02-18

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

Future Oncology2024-10-2911 citations

eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).

Journal of Clinical Oncology2024-06-018 citations

eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.

Journal of Clinical Oncology2024-06-017 citations

TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2023-06-0110 citations

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Cancer Immunology Immunotherapy2023-04-0589 citations

Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study

Cancer Research2022-06-153 citations

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.

Journal of Clinical Oncology2022-06-0117 citations

MEDI5752

Sponsors

Conditions

Phase 1

Phase 2

Related Papers